Clinical trials: HER2-negative Early Breast Cancer
- Condition HER2-negative Early Breast Cancer
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Breast Cancer
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients
This multicenter, prospectively designed study examines whether the Prosigna score influences physician and patient adjuvant treatment selection over and above currently used prognostic factors.
- Trial name
- NCT02625935
- Where
- 4 sites in United States
- Volunteers
- 206 people
- Sponsor
- NanoString Technologies, Inc.